Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03

被引：0
|
作者：
Saura, Cristina
Cortes, Javier
Modi, Shanu
Kim, Sung-Bae
Hamilton, Erika P.
Hurvitz, Sara A.
Krop, Ian E.
Curigliano, Giuseppe
Iwata, Hiroji
Im, Seock-Ah
Herbolsheimer, Pia Maarit
Karnoub, Maha
Gambhire, Dhiraj
Egorov, Anton
Andre, Fabrice
机构：
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Quironsalud Grp, Int Breast Canc Ctr IBCC, Pangaea Oncol, Barcelona, Spain
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Univ Washington, Sch Med, Seattle, WA USA
[7] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[8] Yale Canc Ctr, New Haven, CT USA
[9] Univ Milan, Milan, Italy
[10] IRCCS, European Inst Oncol, Milan, Italy
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst,Natl Univ Hosp, Seoul, South Korea
[13] AstraZeneca, Gaithersburg, MD USA
[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[15] Daiichi Sankyo, Basking Ridge, NJ USA
[16] Univ Paris Saclay, Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1023
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC)
    Kumar, Prashanth Ashok
    Sandhu, Michael
    Sravanthi, Metlapalli Venkata
    Kumar, Vishnu Charan Suresh
    Benjamin, Sam
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 Study
    Krop, I.
    Saura Manich, C.
    Yamashita, T.
    Park, Y. H.
    Kim, S. -B. K.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Denduluri, N.
    Perrin, C.
    Aogi, K.
    Tokunaga, E.
    Im, S. -A.
    Lee, K. S.
    Hurvitz, S.
    Cortes, J.
    Lee, C.
    Chen, S.
    Zhang, L.
    Shahidi, J.
    Yver, A.
    Modi, S.
    SWISS MEDICAL WEEKLY, 2020, : 25S - 25S
  • [23] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd)
    Nozawa, Kazuki
    Kusudo, Maho
    Kureyama, Nari
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [24] A lower dose of trastuzumab deruxtecan (T-Dxd) is effective in controlling HER2-positive metastatic breast cancer
    Hsieh, Y. Pei
    ANNALS OF ONCOLOGY, 2024, 35 : S1394 - S1394
  • [25] Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
    Tarantino, P.
    Kim, S. E.
    Chan, N. N. N.
    Hughes, M. E.
    Smith, K.
    D'Amico, O. R.
    Kusmick, R.
    Pereslete, A. M.
    Alder, L.
    Anders, C.
    Morganti, S.
    Garrido-Castro, A. C.
    Lorusso, P.
    Lustberg, M.
    Sammons, S.
    Lin, N.
    Li, T.
    Tayob, N.
    Rimm, D.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S384 - S385
  • [26] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02)
    Meric-Bernstam, Funda
    Kim, Seung Tae
    Parinyanitikul, Napa
    Moreno, Alberto
    Lin, Chia-Chi
    Gornastolev, Dmitry
    Chindaprasirt, Jarin
    Lugowska, Iwona A.
    Stroyakovskiy, Daniil
    Jassem, Jacek
    Harrison, Michelle L.
    Ostwal, Vikas S.
    Michelini, Flavia
    Jung, Lindsey
    Kuptsova-Clarkson, Nataliya
    Puvvada, Soham D.
    Gan, Hui Kong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] TRASTUZUMAB (T) TOLERABILITY AND ACTIVITY IN HER2+METASTATIC BREAST CANCER (MBC) PATIENTS (PTS) AGED ≥65 YEARS
    Bernardi, A.
    Zucchini, G.
    Rosati, M.
    Rubino, D.
    Quercia, S.
    Cacciari, N.
    Zamagni, C.
    Martoni, A. A.
    ANNALS OF ONCOLOGY, 2010, 21 : 102 - 102
  • [28] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Wang, Xiaojia
    Xu, Binghe
    Gambhire, Dhiraj
    Yung, Lotus
    Meinhardt, Gerold
    Wang, Yibin
    Harbeck, Nadia
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [29] Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
    Oh, D-Y.
    Meric-Bernstam, F.
    Makker, V.
    Oaknin, A.
    Banerjee, S.
    Gonzalez Martin, A.
    Jung, K. H.
    Lugowska, I.
    Manso, L. M.
    Manzano, A.
    Melichar, B.
    Siena, S.
    Stroyakovskiy, D.
    Fielding, A.
    Ma, Y.
    Puvvada, S. D.
    Lee, J-Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1494 - S1495
  • [30] Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
    Meric-Bernstam, F.
    Makker, V.
    Oaknin, A.
    Oh, D. Y.
    Banerjee, S.
    Martin, A. Gonzalez
    Jung, K. H.
    Lugowska, I.
    Manso, L. M.
    Manzano, A.
    Melichar, B.
    Siena, S.
    Stroyakovskiy, D.
    Fielding, A.
    Ma, Y.
    Puvvada, S. D.
    Lee, J. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1274
12345